Alvea’s CEO, Grigory Khimulya, reflects on lessons from the first six months of Alvea’s effort to bring a shelf-stable COVID-19 Omicron vaccine from idea to patients. He discusses inefficiencies in the clinical development process, what make’s Alvea’s culture and approach to clinical development different, and takes questions from the audience on a range of topics.